Contributions
Abstract: PB1753
Type: Publication Only
Background
There is litter data about the influnence of infection of HBV impact on the therapy of aplastic anemia.
Aims
This article is aimed at assessment the HBV reactivation risk in HBsAg-positive or HBsAg-negative, antihepatitis B core antigen antibody (anti-HBc) -positive patients with AA receiving CsA and/or ATG.
Methods
We analysis the clinical data of 60 AA patients with HBV infection out of 201 cases of AA from our center at AA diagnosis during the recent 3 years, and laboratory test data such as levels of liver enzyme, HBV DNA in serum, HBsAg anti-HBs and anti-HBc were monitored. Entecavir（ETV）or lamivudine （LAM） was started when HBV reactivation (defined as detectable HBV DNA) was encountered or as a antiviral prophylaxis regimen for some HBVsAg-positive patients.
Results
Among 60(29.8%) AA patients， 12 were chronically infected (HBsAg positive) and 48 were previously exposed (HBsAg negative/anti-HBc positive). 5 patients（8.33%）who were HBsAg positive and not given any rophylactic antiviral therapy suffered HBV reactivation. 7 patientswho were HBsAg positive but given were found no HBV reactivation. All the 48 patients with negative HBsAg and positive anti-HBc were found no HBV reactivation during the follow-up.
Conclusion
Antiviral prophylaxis should be recommended for HBsAg-positive patients who will receive IST with AA as they had high rate (41.6%) of HBV reactivation. HBV infection were found no influence to the clinic course in AA and antiviral therapy had no influence to the effect of IST.
Session topic: 12. Bone marrow failure syndromes incl. PNH - Clinical
Keyword(s): Aplastic anemia
Abstract: PB1753
Type: Publication Only
Background
There is litter data about the influnence of infection of HBV impact on the therapy of aplastic anemia.
Aims
This article is aimed at assessment the HBV reactivation risk in HBsAg-positive or HBsAg-negative, antihepatitis B core antigen antibody (anti-HBc) -positive patients with AA receiving CsA and/or ATG.
Methods
We analysis the clinical data of 60 AA patients with HBV infection out of 201 cases of AA from our center at AA diagnosis during the recent 3 years, and laboratory test data such as levels of liver enzyme, HBV DNA in serum, HBsAg anti-HBs and anti-HBc were monitored. Entecavir（ETV）or lamivudine （LAM） was started when HBV reactivation (defined as detectable HBV DNA) was encountered or as a antiviral prophylaxis regimen for some HBVsAg-positive patients.
Results
Among 60(29.8%) AA patients， 12 were chronically infected (HBsAg positive) and 48 were previously exposed (HBsAg negative/anti-HBc positive). 5 patients（8.33%）who were HBsAg positive and not given any rophylactic antiviral therapy suffered HBV reactivation. 7 patientswho were HBsAg positive but given were found no HBV reactivation. All the 48 patients with negative HBsAg and positive anti-HBc were found no HBV reactivation during the follow-up.
Conclusion
Antiviral prophylaxis should be recommended for HBsAg-positive patients who will receive IST with AA as they had high rate (41.6%) of HBV reactivation. HBV infection were found no influence to the clinic course in AA and antiviral therapy had no influence to the effect of IST.
Session topic: 12. Bone marrow failure syndromes incl. PNH - Clinical
Keyword(s): Aplastic anemia